Infinitopes Precision Immunomics
PrivateLast Round
Seed
Jan 21, 2026
Total Funding Raised
$70.2M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Infinitopes Precision Immunomics operates in Healthcare & Life Sciences and is based in Oxford. Its latest recorded funding round was a Seed round in January 2026.
Infinitopes Precision Immunomics is a biotechnology company that develops precision cancer vaccines using its proprietary antigen discovery platform and viral vector delivery systems.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Infinitopes Precision Immunomics Comparables
Compare Infinitopes Precision Immunomics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Arcturus Therapeutics Holdings Inc. | 83% | |
| Epitopea | 79% | |
| Nouscom | 79% |
For institutional investors. Book with your work email.
Infinitopes Precision Immunomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jan 21, 2026 | ||||
| Seed | Apr 30, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Infinitopes Precision Immunomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Seed |
| Cancer Research Horizons | Seed |
| Saras Capital | Seed |
| Meltwind Advisory | Seed |
| Kindred Capital | Seed |
| Amplify Partners | Seed |
| Manta Ray Ventures | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 21, 2026
$35.1M raised in Seed funding.
- Mar 20, 2025
Jo Brewer appointed as Non-Executive Director
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 9, 2026
Infinitopes is developing a new generation of off-the-shelf precision cancer vaccines using its proprietary Precision Immunomics(TM) platform, which combines advanced immunology, artificial intelligence and antigen discovery; its lead candidate, ITOP1, progresses through clinical development as the company expands its oncology pipeline in the United Kingdom on Sep 9th '26.
For institutional investors. Book with your work email.
Infinitopes Precision Immunomics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Infinitopes Precision Immunomics's valuation, stock price, and market status.
Is Infinitopes Precision Immunomics a public or private company?
Infinitopes Precision Immunomics is a private company.
What is the current stock price of Infinitopes Precision Immunomics?
Infinitopes Precision Immunomics is a private company, so its shares have no public market price. Caplight tracks Infinitopes Precision Immunomics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Infinitopes Precision Immunomics worth (valuation)?
Valuation information for Infinitopes Precision Immunomics is not publicly available.
Can I buy Infinitopes Precision Immunomics stock?
Infinitopes Precision Immunomics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Infinitopes Precision Immunomics's last funding round?
Infinitopes Precision Immunomics's most recent funding round was Seed on January 21, 2026.
Who are the main investors in Infinitopes Precision Immunomics?
Key investors in Infinitopes Precision Immunomics include Amplify Partners, Octopus Ventures.
Will Infinitopes Precision Immunomics IPO soon?
No public IPO plans have been announced for Infinitopes Precision Immunomics.
How can I track Infinitopes Precision Immunomics secondary market activity?
Caplight tracks bids, offers, and trades in Infinitopes Precision Immunomics's shares on secondary markets.